Global Phase IIb/III Microbicide Clinical Trials

<div><p><b>Red circle:</b> Carraguard. Sponsored by Population Council. Phase III study of the efficacy and safety of the microbicide Carraguard in preventing HIV seroconversion in women.</p> <p><b>Blue cross: 2% and 0.5% PRO2000.</b> Sponsored by Microbicide Development Programme. A phase III, multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the effectiveness and safety of 0.5% PRO2000 and 2% PRO2000 gels for the prevention of vaginally acquired HIV infection.</p> <p><b>Yellow cross: BufferGel and 0.5% PRO2000.</b> Sponsored by US National Institutes of Health. HPTN 035: Phase II/IIb safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 gel (P) for the prevention of HIV infection in women.</p> <p><b>Green star: Cellulose sulphate—East and Southern Africa.</b> Sponsored by CONRAD. Randomised controlled trial of 6% cellulose sulphate gel and the effect on vaginal HIV transmission.</p> <p><b>Green star: Cellulose sulphate—Nigeria.</b> Sponsored by Family Health International. Phase III trial of cellulose sulphate for HIV prevention. <b>Pink box: C31G (SAVVY).</b> Sponsored by Family Health International. Phase III trial of SAVVY in Ghana and Nigeria.</p></div

Examples of research questions for the three research domains.

<p>*As noted above, depending on how the question is phrased and the research is designed; some of these questions can be addressed in several research domains.</p

Defining research to improve health systems.

<p>*How amenable the research outputs are to adaptation, scaling up or use or in other contexts or locations.</p

Research to improve health systems.

<p>Research to improve health systems.</p